恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究*

doi:10.3969/j.issn.1672-5069.2022.03.006

Abstract

Abstract: Objective The purpose of this study was to observe the application of entecavir and magnesium isoglycyrrhizinate combination in the treatment of patients with chronic hepatitis B (CHB). Methods A total of 98 patients with CHB were enrolled in our hospital between January 2019 and February 2020, and were randomly divided into control (n=49) and observation group (n=49), receiving entecavir or entecavir and magnesium isoglycyrrhizinate combination therapy for 48 weeks. Serum hyaluronan (HA), laminin (LN), type-IV collagen (CIV) and type-III procollagen (PIIIP) levels were detected by radioimmunoassay. Serum interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 10 (IL-10) and tumor necrosis factor α (TNF-α) levels were detected by ELISA. The peripheral blood T lymphocyte subsets were detected by flow cytometry. Results At the end of 48 week observation, serum ALT normalization rate in the observation group was 87.8%, significantly higher than 71.4%(P＜0.05) in the control; serum ALT and AST levels in the combination group were (32.3±6.9)U/L and (38.3±4.7)U/L, both significantly lower than [(47.5±7.6)U/L and (52.9±5.1)U/L, respectively, P＜0.05] in the control; serum HA and PⅢP levels were (90.6±9.5)ng/mL and (141.6±32.6)ng/mL, both significantly lower than [(126.8±14.6)ng/mL and (168.2±29.9)ng/mL, respectively, P＜0.05] in the control; serum IL-4 and TNF-α levels were (48.8±7.9)ng/L and (11.3±1.9)ng/L, significantly lower than [(62.6±8.8)ng/L and (18.5±1.7)ng/L, respectively, P＜0.05], while serum IL-10 level was (19.2±2.5)ng/L, significantly higher than [(12.7±3.4)ng/L, P＜0.05] in the control; the percentage of peripheral blood CD4⁺ cells and the ratio of CD4⁺/CD8⁺ cells were (43.5±5.5)% and (1.6±0.2), both significantly higher than [(38.4±4.7)% and(1.4±0.4), respectively, P＜0.05] in the control group. Conclusion The application of entecavir and magnesium isoglycyrrhizinate combination in the treatment of patients with CHB could effectively improve liver function test normal, inhibit the process of liver fibrosis, which might be related to the inhibition of inflammatory reaction and modulation of immune system.

Key words: Hepatitis B, Entecavir, Magnesium isoglycyrrhizinate, Therapy

Huang Junrong, Wu Changru, Wu Jianlin. Short-term observation of entecavir and magnesium isoglycyrrhizinate in treatment of patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2022, 25(3): 327-330.

References

[1] 赖思敏,赖小丽,黄汐,等.核苷(酸)类似物经治序贯聚乙二醇干扰素治疗慢性乙型肝炎的荟萃分析.中国感染与化疗杂志,2019,36(5):489-494.
[2] Hees SV, Cuypers B, Bourgeois S, et al. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol, 2021,362(4):104283.
[3] Wang J, Guo S, Zeng M, et al. Observation of the curative effect of device-guided rehabilitation on respiratory function in stable patients with chronic obstructive pulmonary disease. Medicine,2019,98(8):e14034.
[4] Yang L, Zhong HZ, Xiao QL, et al. Precise analysis of the effect of basal core promoter/precore mutations on the main phenotype of chronic hepatitis B in mouse models. J Med Virol,2020,92(12):26025.
[5] Rong G, Chen Y, Yu Z, et al. Synergisticeffect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-Blind, placebo-controlled trial. J Infect Dis, 2020,21(3):266-270.
[6] Zhang C, Wang A, Wang H, et al. Entecavir-loaded poly (lactic-co-glycolic acid) microspheres for long-term therapy of chronic hepatitis-B: Preparation and in vitro and in vivo evaluation. Int J Pharm, 2019,5(4):27-34.
[7] Boglione L, Benedetto ID, Lupia T, et al. Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study. Arch Virol,2021:166(4):1125-1131.
[8] 中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):V-XVI.
[9] Chen MB,Wang H,Zheng QH, et al. Effectiveness of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: A protocol for systematic review and meta-analysis. Medicine, 2019, 98(34):e16943.
[10] Inoue T, Kusumoto S, Iio E, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol,2021,21(3):1016-1018.
[11] Yang YZ, Liu ZH, Wang SC, et al. Magnesium isoglycyrrhizinate alleviates fructose-induced liver oxidative stress and inflammatory injury through suppressing NOXs. Eur J Pharmaco, 2020,883(16):173314.
[12] Jiang W, Xu S, Guo H, et al. Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis. J Cell Mol Med, 2020,24(13):15230.
[13] Li TS, Chen L, Wang SC, et al. Magnesium isoglycyrrhizinate ameliorates fructose-induced podocyte apoptosis through downregulation of miR-193a to increase WT1. Biochem Pharmacol, 2019,166(15):139-152.
[14] Inoue T, Kusumoto S, Iio E, et al. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol,2021,17(2):18-19.
[15] Xie C, Li X, Zhu J, et al. Magnesium isoglycyrrhizinate suppresses LPS-induced inflammation and oxidative stress through inhibiting NF-κB and MAPK pathways in RAW264.7 cells. Bioorgan Med Chem, 2019, 27(3):516-524.
[16] 涂杰霞,王安娜,廖若汐.干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究.实用肝脏病杂志,2019,22(5):648-651.
[17] Mak L, Lee C, Cheung K, et al. Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long‐term nucleoside analogue. Liver Intl,2019,39(7):1217-1225.
[18] Lee SW, Kim SU. Tenofovir disoproxil fumarate vs entecavir in patients with chronic hepatitis B and renal impairment—still an open issue. Aliment Pharm Ther, 2020, 52(5):889-890.
[19] Mei F,Yu J, Li M, et al. Magnesium isoglycyrrhizinate alleviates liver injury in obese rats with acute necrotizing pancreatitis. Pathol Res Pract, 2018,215(1):30-35.
[20] Yang YZ, Zhao XJ, Xu HJ, et al. Magnesium isoglycyrrhizinate ameliorates high fructose-induced liver fibrosis in rat by increasing miR-375-3p to suppress JAK2/STAT3 pathway and TGF-β1/Smad signaling. Acta Pharmacol Sin,2018,40(7):879-894.

Short-term observation of entecavir and magnesium isoglycyrrhizinate in treatment of patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	He Yajuan, Wang Fei, Yao Naijuan, et al. Hepatitis B whole x gene promotes inflammation reaction of hepatic stellate cells and triggers hepatocyte apoptosis in vitro [J]. Journal of Practical Hepatology, 2022, 25(3): 323-326.
[2]	Zou Donghua, Mi Jianwei, Li Yuling, et al. Rescued therapy of patients with chronic hepatitis B and rtA181V/T mutation by adefovir dipivoxiland entecavir or tenofovir combination [J]. Journal of Practical Hepatology, 2022, 25(3): 331-334.
[3]	Luo Ke, Ding Li, Liu Mei. Serum miR-21 and miR-148b levels in patients with chronic hepatitis B and their predictive value for liver tissue inflammation grading and fibrosis staging [J]. Journal of Practical Hepatology, 2022, 25(3): 335-338.
[4]	Wang Guangli, Xu Huan, Dong Dandan, et al. Entecavir resistance gene mutation in nucleosi(t)de-treated patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(3): 339-342.
[5]	Yan Zhaolan, Zu Hongmei, Cai Changxia, et al. Clinical features of chronic hepatitis B viral infected individuals with low serum alanine aminotransferase levels: clues for early liver biopsies [J]. Journal of Practical Hepatology, 2022, 25(3): 343-346.
[6]	Li Chunhua, Li Zhongxin, Zhang Chunlei, et al. Diagnostic performance of serum FGF-21, PDGF-BB and FBRS levels on significant liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(3): 347-350.
[7]	Jiang Yuemeng, Ma Yuqi, Kan Chunming, et al. Early impact of nucleos(t)ide analogs on renal function tests in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(3): 351-354.
[8]	Chai Xiaozhe, Zhu Xiafeng, Luo Chenglin, et al. Comparison of virologic response in patients with chronic hepatitis C and hepatitis C viral genotype 1b infection receiving pan-genotype or precise genotype-specific direct antiviral agent therapy [J]. Journal of Practical Hepatology, 2022, 25(3): 355-358.
[9]	Hu Chunxia, Yang Jiaonan, Zhang Fengxiao et al. Efficacy and safety of glecaprevir/pibrentasvir therapy in the treatment of patients with chronic hepatitis C and genotype 1b infection [J]. Journal of Practical Hepatology, 2022, 25(3): 359-362.
[10]	Chen Yejing, Lu Qingping, Gu Shaoying. Comparison of therapeutic efficacy of magnesium isoglycyrrhizinate and compound glycyrrhizin monoamine in treatment of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(3): 371-374.
[11]	Yang Haihua, Zhou Cong, Shen Guoqiang, et al. Clinical feature of tigecycline-induced liver injuries in 134 elderly patients with infection and underlying diseases [J]. Journal of Practical Hepatology, 2022, 25(3): 375-378.
[12]	Wang Shisong, Lin Huixiong, Zhang Taisheng, et al. Short-term observation of metformin and dapagliflozin combination therapy in the treatment of patients with T2DM and NAFLD and their impact on serum dipeptidyl peptidase 4 and C-peptide levels [J]. Journal of Practical Hepatology, 2022, 25(3): 379-382.
[13]	Shen Yanglin, Tan Keping, You Zhonglan, et al. Short-term efficacy of sequential plasma exchange and dual plasma molecular adsorption system combination in treatment of patients with HBV-ACLF [J]. Journal of Practical Hepatology, 2022, 25(3): 387-390.
[14]	Sun Yanan, Zeng Qinghuan, Liu Yuanzhi, et al. Influencing factors for prognosis of patients with acute-on-chronic liver failure and moderate or severe esophageal varices [J]. Journal of Practical Hepatology, 2022, 25(3): 391-394.
[15]	Zhan Huizhen, Du Yaqin, Wang Songjiao. Seven-day observation of concentrated ascites reinfusion and terlipressin combination therapy in the treatment of patients with liver cirrhosis and refractory ascites [J]. Journal of Practical Hepatology, 2022, 25(3): 395-398.